Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2017-04-27 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2016年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and proceedings of the 2016 Annual General Meeting (AGM) of 华兰生物工程股份有限公司. It details the legality of the meeting's convening, attendance, proposals, and voting results. It does not contain financial statements or detailed financial performance data, nor is it a report or announcement of financial results. Instead, it is a legal opinion related to the AGM process and resolutions. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the validity and results of the shareholder meeting and voting.
2017-04-27 Chinese
第六届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of 华兰生物工程股份有限公司 regarding the approval of the company's 2017 first quarter report and a capital increase proposal for an affiliated company. It includes voting results and confirms the report's compliance with legal and regulatory requirements. The document is short (629 characters) and primarily announces the approval of the quarterly report rather than containing the full financial data or analysis itself. Therefore, it is not the Interim/Quarterly Report (IR) itself but an announcement related to it. Given the nature of the content and the short length, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2017-04-26 Chinese
第六届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 华兰生物工程股份有限公司, detailing the decisions made at the sixth board meeting, including approval of the 2017 first quarter report and a related party transaction. It references the full quarterly report being published elsewhere and does not contain the actual financial statements or detailed report content itself. The document is short (658 characters) and serves as an announcement of board decisions and approvals rather than the report itself. Therefore, it fits best under Board/Management Information (MANG), as it announces board meeting resolutions and management decisions.
2017-04-26 Chinese
关于对参股公司华兰基因工程有限公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an increase in capital investment in an associate company and related party transaction. It includes details about the transaction, the parties involved, the approval process by the board, independent director opinions, and compliance with regulations. The document is relatively short (1721 characters) and structured as a formal announcement rather than a detailed financial report. It does not contain comprehensive financial statements or detailed financial analysis. The content fits the category of a Capital/Financing Update (CAP) because it reports on a capital increase and related party transaction, which are financing activities. It is not an Annual Report, Interim Report, or Audit Report, nor is it a simple regulatory filing or report publication announcement. Therefore, the best classification is CAP with high confidence.
2017-04-26 Chinese
2017年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2017 年第一季度报告全文" which translates to "2017 First Quarter Report Full Text." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and detailed notes on financial performance for the first quarter of 2017. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2017
2017-04-26 Chinese
2017年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2017 年第一季度报告正文" which translates to "2017 First Quarter Report Main Text." It contains detailed financial data such as revenue, net profit, cash flow, shareholder information, and explanations of financial changes for the quarter. The presence of actual financial statements and substantive financial data for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is about 5800 characters, which is sufficient to be the report itself rather than a brief announcement. There is no indication that this is merely a publication announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2017
2017-04-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.